Knobbe Martens Lawyers Explore Trademark Risks of Athlete Jersey Number Branding in Sports Business Journal
In their recent Sports Business Journal article, Knobbe Martens lawyers Jonathan Hyman, Jonathan Menkes, and Edward Nester examine a growing IP challenge in the sports industry: what happens when an...
Life Science Update | April 2026
One Battle After Another: Broad Institute Wins at PTAB in CRISPR Dispute Eric Furman, Ph.D. & Alistair J. McIntyre Interference proceedings, though increasingly rare, are heavily evidence-based and determine which...
Aerospace Update | April 2026
Space Force Awards Kratos $447 Million Contract for Missile Warning Tracking Lizzy T. Do & Scott Cromar Kratos wins $447 million contract with U.S. Space Force to develop a ground...
Litigation Update | April 2026
No Do-Overs: Voluntary Dismissal Does Not Reset Deadline for Stay Jeremiah S. Helm, Ph.D. A respondent in an ITC proceeding may not seek a mandatory stay of their refiled declaratory...
NOVONIX Emerges as a Winner in the U.S. Battery Materials Race
Key Takeaways: The domestic battery race is being won by companies, such as NOVONIX, that are developing innovative IP and meeting critical operational and/or commercial milestones based on that IP....
Yi Zhou and Ben Katzenellenbogen Analyze Inconsistent Applications of the Alice Test in Software Patent Litigation for Reuters Westlaw
In a recent Reuters Westlaw article, Knobbe Martens lawyers Yi Zhou and Ben Katzenellenbogen discuss the Federal Circuit’s decision in USAA v. PNC Bank and its implications for patent eligibility...
FDA Emphasizes Use of Real-World Evidence for Medical Device Makers
The U.S. Food and Drug Administration (FDA) has increasingly emphasized the use of real-world evidence (RWE) to support regulatory decision-making for medical devices. As medical technologies evolve and data sources...
FDA Announces “RAPID” Pathway for Expedited Access to Breakthrough Devices by Medicare Population
On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) announced “a new pathway designed to expedite access to certain FDA-designated Class II...
AI Risks With the Patent Office: What Life Science Companies Should Be Asking Now
Key Takeaway(s): AI tools are reshaping patent preparation and prosecution, but statements made to the USPTO are permanent, and AI-generated inaccuracies don’t come with warning labels. Efficiency gains are real, but...
